ALSO NOTED: Rebif gets EU nod; Bayer buys Citracal;

> Merck Serono got the EU nod to market a new version of the relapsing multiple sclerosis med Rebif. The new formulation, designed to be better tolerated when injected, will launch next month; the company is authorized to sell it in all 27 E.U. countries, plus Iceland, Liechtenstein and Norway. Release

> Bayer is buying the over-the-counter calcium supplement Citracal from Mission Pharmacal. The financial terms weren't disclosed, but the product sold some $47 million last year. Report

> Roche lost its bid to overturn an Australian ban on advertising the weight-loss drug Xenical. Report

> Contract manufacturer Catalent Pharma has signed a deal to increase production of Danish drug maker ALK-Abelló's tablet-based allergy vaccine Grazax, using a newly built production line funded by the drug company. Report

And Finally... Why aren't markets moved by government investigations of Big Pharma shenanigans? The Financial Times wants to know--especially when almost every major drug maker is under scrutiny, and a few have even pleaded guilty to corporate criminal charges. Report (sub. req.)